SURPASS-CVOT: Tirzepatide noninferior to dulaglutide on MACE in T2D/ASCVD
Key Questions
What were the key findings of the SURPASS-CVOT trial?
Tirzepatide was noninferior to dulaglutide for major adverse cardiovascular events (MACE) in patients with type 2 diabetes and ASCVD, despite superior weight loss and glycemic control but no LDL reduction.
What does SURPASS-CVOT imply for GLP-1/incretin therapies in T2D?
It reinforces the cardiovascular benefits of GLP-1 receptor agonists and incretins in T2D prevention, suggesting lipid-independent (pleiotropic) effects beyond LDL lowering.
How does the ACHIEVE-4 trial relate to these findings?
Eli Lilly's oral orforglipron in ACHIEVE-4 demonstrated CV safety, weight loss, and lipid improvements, adding to evidence for oral incretins post-2026 guidelines.
NEJM letter: tirzepatide noninferior on MACE despite superior WL/glycemic control but no LDL reduction—hints at lipid-independent CV benefits. Reinforces GLP1/incretin role in ABCs/T2D prevention post-2026 guideline; probes pleiotropic effects amid LDL-first paradigm; orforglipron ACHIEVE-4 oral adds CV safety/WL/lipid wins.